Zanzalintinib plus paclitaxel for recurrent uterine cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial combines an experimental pill called zanzalintinib with a standard chemotherapy (paclitaxel) for people with advanced or recurrent high-grade uterine cancer who have already tried platinum-based chemotherapy. The goal is to see if this combination can help shrink or control the cancer better than standard options alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an aggressive type of uterine cancer (high-grade endometrioid, serous, mixed, or uterine carcinosarcoma) that has returned after treatment and you've already tried platinum-based chemotherapy or couldn't tolerate it.
- You've had only 1 or 2 previous cancer treatments (like chemotherapy, immunotherapy, or targeted therapy).
- Your cancer shows up on scans (CT or MRI) and can be measured.
- You are generally active and able to do most daily activities (ECOG score 0-2).
- Your blood counts and organ function (kidneys, liver) are adequate based on tests within the last 2 weeks.
- You are not pregnant, agree to use effective contraception, and have no major health conditions that could interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This trial is testing an experimental therapy against standard chemotherapy for people with endometrial cancer that has come back. The study looks for a certain protein (HER2) on cancer cells to decide which treatment group you may be in.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has worsened after previous treatments. The goal is to see if zanzalintinib can help control the cancer.
This trial tests a maintenance therapy combining zanzalintinib and etoposide after you've completed high-dose chemotherapy and a stem cell transplant for germ cell cancer. The goal is to see if this drug combination helps prevent the cancer from coming back.
This trial is testing a new drug (zanzalintinib) alone or with pembrolizumab to see if it can stop cancer from coming back in people with colorectal cancer who have no visible cancer on scans but still have tumor DNA in their blood.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.